Leonard Zehr, Author at BioTuesdays

Feature

XOR Labs pioneering technology to expand lung transplantation

By Len Zehrs Closely-held XOR Labs hopes to dramatically increase the number of lungs suitable for transplantation with its Ex-Vivo Lung Perfusion (EVLP) technology. “Only about 20 out of every 100 donated lungs are...

June 12, 2018

Feature

NanoSphere spearheads delivery of medical nano-encapsulated THC/CBD

By Len Zehrs NanoSphere Health Sciences (CSE:NSHS; OTC:NSHSF) has developed a newly-patented delivery technology that increases the bioavailability and bioactivity of its Evolve line of gel-like cannabinoids for the...

June 5, 2018

Markets

HCW starts Synthetic Biologics at buy; PT $1

H.C. Wainwright initiated coverage of Synthetic Biologics (NYSE AMERICAN:SYN) with a “buy” rating and price target of $1. The stock finished at 25 cents on May 17. Analyst Edward White writes that the new coverage is...

May 21, 2018

Feature

Nanobiotix pioneering nanomedicine in new paradigm against cancer

By Len Zehrs France’s Nanobiotix (Euronext:NANO) is hoping to change the paradigm for cancer treatment with a single nanomedicine applicable across oncology for millions of patients. “What differentiates us is that we...

May 15, 2018

Feature

CellAegis to complete enrolment in U.S. autoRIC trial by end of 2018

By Len Zehrs In addition to several large ongoing investigator-sponsored studies in Europe and Canada using its autoRIC device for automated remote ischemic conditioning (RIC), closely-held CellAegis Devices expects its...

May 8, 2018

Feature

Aimmune readies filing for FDA approval of peanut allergy treatment

By Len Zehrs On the heels of positive data from its PALISADE pivotal trial, Aimmune Therapeutics (NASDAQ:AIMT) plans to submit a biologics license application with the FDA by the end of 2018 for its peanut allergy...

May 1, 2018

Feature

Cyclica offers Pharma a novel cloud platform to increase R&D productivity

By Len Zehrs During the past four years, closely-held Cyclica has developed and validated a patented structure-based and AI-augmented proteome-screening platform, known as Ligand Express. “The platform enables critical...

April 24, 2018

Feature

Moberg Pharma parlaying topical niche brands to fuel innovation engine

By Len Zehrs Sweden’s Moberg Pharma (OMX:MOB) is focused on maximizing the potential of its market leading position in over-the-counter sales of topical dermatology products to drive development of new therapies for the...

April 17, 2018

Feature

Tear Film Innovations readies launch of iLux device for dry eye disease

By Len Zehrs Closely-held Tear Film Innovations plans to formally launch at two upcoming medical conferences its iLux medical device to treat Meibomian gland dysfunction, the leading cause of dry eye disease. The...

April 10, 2018

Feature

Myomo scaling up distribution of MyoPro robotic arm brace

By Len Zehrs Myomo (NYSE American:MYO) is moving from a controlled introduction over the past few years to a scale up sales and distribution of its MyoPro product line of lightweight, non-invasive, powered arm braces to...

April 3, 2018

Author - Leonard Zehr

XOR Labs pioneering technology to expand lung transplantation

NanoSphere spearheads delivery of medical nano-encapsulated THC/CBD

HCW starts Synthetic Biologics at buy; PT $1

Nanobiotix pioneering nanomedicine in new paradigm against cancer

CellAegis to complete enrolment in U.S. autoRIC trial by end of 2018

Aimmune readies filing for FDA approval of peanut allergy treatment

Cyclica offers Pharma a novel cloud platform to increase R&D productivity

Moberg Pharma parlaying topical niche brands to fuel innovation engine

Tear Film Innovations readies launch of iLux device for dry eye disease

Myomo scaling up distribution of MyoPro robotic arm brace

General

More